STOCK TITAN
  1. Home
  2. News
  3. TNXP

Tonix Pharmaceut - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.

Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.

One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.

The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.

Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.

For more information, visit Tonix Pharmaceuticals Holding Corp.

News

Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces EVERSANA as partner for the launch strategy of Tonmya, a potential first-line non-opioid analgesic for fibromyalgia. Positive Phase 3 trial results support NDA submission to FDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
-
News

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces promising results for TNX-1500, a third-generation anti-CD40L mAb with reduced thrombosis risk and potential peak sales exceeding €5B per year. TNX-1500 shows positive PK properties in animal studies, supporting monthly dosing, and has multiple potential indications in transplantation and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News

Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces presentation of additional data from positive Phase 3 RESILIENT trial of Tonmya™ for fibromyalgia management at The 6th International Congress on Controversies in Fibromyalgia. The company focuses on CNS disorders and plans to submit an NDA to the FDA in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
News

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. completes Phase 1 trial of TNX-1500, a potential treatment for organ transplant rejection and autoimmune disorders. Positive clinical data from Sanofi's frexalimab in multiple sclerosis. Topline results expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive results from a clinical pharmacokinetic bridging study of Tonmya in ethnic Japanese and Chinese volunteers. The study supports plans to file a Clinical Trial Notification in Japan and an Investigational New Drug application in China for a registration-enabling Asian Phase 3 study. Tonmya's market exclusivity is backed by patents in Japan, China, Hong Kong, and Taiwan. The New Drug Application submission to the U.S. FDA for Tonmya's approval for fibromyalgia management is scheduled for the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
-
News

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Rhea-AI Summary
Tonix Pharmaceuticals (TNXP) has developed a bedtime drug targeting fibromyalgia's poor sleep quality, showing promising results in reducing widespread pain. The drug, Tonmya, demonstrated significant pain improvement in a phase 3 study, with a potential FDA approval in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
News

Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces CEO's participation at BIO CEO & Investor Conference to discuss the company's pipeline of development candidates, including positive Phase 3 studies for fibromyalgia treatment and plans for NDA submissions. The company's focus on CNS disorders and rare diseases, breakthrough therapy designation for TNX-1300, and vaccine development for smallpox and COVID-19 are highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
conferences
-
News

Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction

Rhea-AI Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) reported positive Phase 3 trial results for its non-opioid painkiller for fibromyalgia, achieving the primary endpoint with a p-value of 0.00005. The drug, Tonmya, showed promising results in reducing pain, improving sleep, and reducing fatigue. With potential FDA approval in 2025, Tonmya could offer a new treatment option for fibromyalgia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announces positive Phase 3 data for Tonmya™ (TNX-102 SL) for fibromyalgia management, showcasing significant reduction in pain, fatigue, and sleep disturbance. Plans to file for FDA approval in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.43%
Tags
clinical trial fda approval
News

Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia

Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. engages Rho, Inc. for NDA submission of Tonmya™, a potential first-line therapy for fibromyalgia. Positive Phase 3 results show significant pain reduction compared to placebo, with plans for NDA submission in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none

FAQ

What is the current stock price of Tonix Pharmaceut (TNXP)?

The current stock price of Tonix Pharmaceut (TNXP) is $9.17 as of February 21, 2025.

What is the market cap of Tonix Pharmaceut (TNXP)?

The market cap of Tonix Pharmaceut (TNXP) is approximately 54.1M.

What is the main focus of Tonix Pharmaceuticals Holding Corp.?

Tonix focuses on developing, licensing, and commercializing therapeutics to treat and prevent human diseases, with a primary focus on central nervous system disorders.

What is Tonmya?

Tonmya is a treatment developed by Tonix Pharmaceuticals aimed at addressing PTSD. It is one of the company's key projects.

What are TNX-601 and TNX-801?

TNX-601 (tianeptine oxalate) is a candidate for daytime treatment of PTSD and TNX-801 is a synthetic version of the horsepox virus, intended as a potential smallpox-preventing vaccine.

What is TNX-1500?

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand, being developed to prevent allograft rejection and treat autoimmune diseases.

Which institutions is Tonix Pharmaceuticals affiliated with?

Tonix has established partnerships with reputable institutions, including Massachusetts General Hospital, to support their research and development projects.

How can I get more information about Tonix Pharmaceuticals?

More information about Tonix Pharmaceuticals can be found on their official website, www.tonixpharma.com.

What areas of disease does Tonix Pharmaceuticals focus on?

Tonix focuses on central nervous system disorders, organ transplant rejection, autoimmunity, cancer, rare diseases, and infectious diseases.

What stage are TNX-601 and TNX-801 in?

Both TNX-601 and TNX-801 are at the pre-IND (Investigational New Drug) application stage.

Who can I contact for investor relations at Tonix Pharmaceuticals?

For investor relations, you can contact Jessica Morris at investor.relations@tonixpharma.com or Peter Vozzo at peter.vozzo@westwicke.com.

Who can I contact for media inquiries at Tonix Pharmaceuticals?

For media inquiries, you can contact Katie Dodge at kdodge@lavoiehealthscience.com.
Stock TNXP logo
Tonix Pharmaceut

Nasdaq:TNXP

TNXP Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

TNXP Stock Data

54.06M
5.59M
0.17%
0.23%
5.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHATHAM